ProtoKinetix claims breakthrough in anti-aging research

British Colombia-based biotech company ProtoKinetix says that further scientific testing has underlined how AAGP molecules can arrest the aging effect on the skin and prevent UV damage - a discovery that could lead to a number of skin care and sun care applications.

AAGP is a family of glycoproteins that have been found to provide anti-inflammatory, anti-aging and UV protection properties for the skin, which the company claims could have a major impact on the cosmetics and personal care industry.

CosmeticsDesign.com reported on the progress of the company's research back in October, highlighting the fact that it was getting closer towards providing the industry with solid evidence to prove its research in the field.

The next step has been to trial the research, a step that is said to have confirmed that the technology could ultimately slow down the aging process of human skin. The trials have been carried out in conjunction with an unnamed cosmetics company.

ProtoKinetix says that the trials have concluded that very low concentrations of AAGP molecules have proven to be a powerful additive compared to the noted anti-aging compound coenzyme Q10, and that further testing has highlighted cell integrity and cell function even within high concentrations of the cell molecule.

Furthermore, other tests concerning UV exposure have found that AAGP molecules not only help protect against UV light, but it can actually help at a molecular level to induce the repair of damaged cells.

Capitalizing on these trial results, the company says that the next step will be to launch AAGP into markets where no regulatory approval is necessary for fast tracking.

This should see the incorporation of the technology into skin care applications for its anti-oxidant and anti-aging properties, as well as a variety of sun care products for both its protection and repair properties.

In anticipation of this move the company has entered into talks with chemical companies to ramp up production of the AAGP molecule family, with a view to fulfilling six separate application developments with universities, institutions and corporations.ProtoKinetix says that the course of the manufacturing and application developments will ultimately dictate the development of the technology, but is expecting that it will also help to quickly establish a strong market value.